A method for decreasing formation of one or more chemiexcitation-induced dark cyclobutane pyrimidine dimers (dCPDs) in a cell or DNA molecule in a subject, who has been exposed to UV radiation, is provided. The method comprises administering to the subject an effective amount of a dCPD quencher within 8 hours after the exposure. The dCPD quencher is selected from the group consisting of ellagic acid, Porphyra Umbilicalis Extract (including Porphyra Umbilicalis Extract (and) Sodium Lactate (and) Lecithin), mycosporine-like amino acids (MAAs) and synthetic analogues thereof, Scutellaria Baicalensis Root Extract, Chrysanthemum Morifolium Leaf Extract, ferulic acid, fused-ring cyanoacrylates, curcumin, epigallocatechin gallate, Scutellaria Baicalensis Root Extract (and) Acacia Catechu Wood Extract, sorbic acid, Polygonum Cuspidatum Root Extract, Acacia Catechu Extract, dipicolinic acid, squalene, Lonicera Japonica (Honeysuckle) Flower Extract, beta-carotene and combinations thereof. The dCPD quencher may be administered to the subject in the absence of UV radiation.

Active ingredient capsules are proposed which are obtainable by, with the input of mechanical and thermal energy, (a) dissolving and/or dispersing proteins, polysaccharides and cellulose derivatives in water, (b) adding the active ingredients to be encapsulated, (c) hardening the resulting coacervates with the addition of tannins and optionally (d) then subjecting them to a spray drying.

The invention relates to a method for producing an extract of a matrix of vegetable origin, particularly a plant, involving a solid-liquid extraction by means of an aqueous solution containing at least one, preferably agro-sourced, non-ionic amphiphilic compound, at a concentration at least equal to the minimum hydrotrope concentration thereof.

Formulations to treat skin discoloration via a multi-modal approach are provided in some embodiments in which select ingredients work together to effectively brighten skin and treat hyperpigmentation. In other embodiments, soothing redness correction formulations are provided. In yet other embodiments, certain formulations are renewal formulations adapted to treat the eye area to, for example, reduce laxity, puffiness, wrinkles and/or dark circles around the eye.

Formulations to treat skin discoloration via a multi-modal approach are provided in some embodiments in which select ingredients work together to effectively brighten skin and treat hyperpigmentation. In other embodiments, soothing redness correction formulations are provided. In yet other embodiments, certain formulations are renewal formulations adapted to treat the eye area to, for example, reduce laxity, puffiness, wrinkles and/or dark circles around the eye.

A method of treating skin is disclosed. The method can include topically applying to a peron's skin a composition comprising 0.0001% to 5% w/w of a hydrolyzed algae extract comprising exopolysaccharides from Halymenia durvillei, and 0.0001% to 5% w/w of a saccharide isomerate comprising an exopolysaccharide synthesized by Vibrio alginolyticus, wherein at least one of skin permeability is decreased, filaggrin production is increased, skin moisture is increased, occludin production is increased, or TNF? production is inhibited in the skin.

A method of treating skin is disclosed. The method can include topically applying to a peron's skin a composition comprising 0.0001% to 5% w/w of a hydrolyzed algae extract comprising exopolysaccharides from Halymenia durvillei, and 0.0001% to 5% w/w of a saccharide isomerate comprising an exopolysaccharide synthesized by Vibrio alginolyticus, wherein at least one of skin permeability is decreased, filaggrin production is increased, skin moisture is increased, occludin production is increased, or TNF? production is inhibited in the skin.

A method of treating the skin or hair on a dog containing an effective amount of an ectoparasiticide previously applied to the skin or hair, comprising applying a quantity of a cleansing composition directly to the skin or hair, wherein the treatment does not result in reducing the efficacy of the ectoparasiticide against adult fleas (C. felis) or adult ticks (R. sanguineus) below 90% efficacy for at least a month after application of the ectoparasiticide; wherein the cleansing composition comprises about 1-3% glycerin; about 2-4% silicone copolyol esters, water and is essentially free of surfactant.

A topical composition comprising a non-denatured, broken-up and dried Porphyridium biomass that is not further processed and a pharmaceutically or cosmetically acceptable carrier useful for cosmetic treatments is described.

A topical composition comprising a non-denatured, broken-up and dried Porphyridium biomass that is not further processed and a pharmaceutically or cosmetically acceptable carrier useful for cosmetic treatments is described.